China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its HDM1005, a long-acting agonist targeting the GLP-1 receptor and GIP receptor. The drug is set for development to treat adult patients with heart failure with preserved ejection fraction (HFpEF) and obesity or overweight.
Pre-Clinical Study Results
Pre-clinical studies have shown that HDM1005, a Category 1 chemical, can activate GLP-1 receptors and GIP receptors, promote insulin release, inhibit appetite, and exert significant effects on improving glucose tolerance, lowering blood sugar, and weight loss. Existing data indicates that HDM1005 has good medicinal properties and safety.-Fineline Info & Tech
Leave a Reply